Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis

被引：0

作者：

Hauser, S. L. ^{[1
]}

Kappos, L. ^{[2
]}

Montalban, X. ^{[3
]}

Bar-or, A. ^{[4
]}

Giovannoni, G. ^{[5
]}

Model, F. ^{[6
]}

Hubeaux, S. ^{[6
]}

Mehta, L. ^{[7
]}

Wolinsky, J. S. ^{[8
]}

机构：

[1] Univ Calif San Francisco, San Francisco, CA 94143 USA

[2] Univ Basel, Univ Basel Hosp, Basel, Switzerland

[3] Univ Toronto, Div Neurol, Toronto, ON, Canada

[4] Univ Penn, Philadelphia, PA 19104 USA

[5] Queen Mary Univ London, London, England

[6] F Hoffmann La Roche Ltd, Basel, Switzerland

[7] Genentech Inc, San Francisco, CA 94080 USA

[8] Univ Texas Hlth Sci Ctr Houston UTHlth, McGovern Med Sch, Houston, TX USA

来源：

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EPO1250

引用

页码：496 / 496

页数：1